US2007060562A1PendingUtilityA1

Novel crystal form of pyrrolidylthiocarbapenem derivative

Assignee: SAITOH IZUMIPriority: Mar 31, 2000Filed: Nov 10, 2006Published: Mar 15, 2007
Est. expiryMar 31, 2020(expired)· nominal 20-yr term from priority
A61P 31/00A61P 31/04C07D 477/20C07B 2200/13
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A novel crystal of a pyrrolidylthiocarbapenem derivative having excellent stability is provided. According to the present invention, a crystal of (+)-(4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3 [[(3S,5S)-5-(sulfamoylaminomethyl)pyrrolidin-3-yl]thio]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid having a diffraction pattern in powder X-ray diffraction preferably having main peaks at diffraction angles (2θ)=13.04, 14.98, 15.88, 16.62, 20.62, 21.06, 22.18, 23.90, 26.08, 28.22 and 28.98 (degrees) is provided.

Claims

exact text as granted — not AI-modified
1 . A crystal of (+)-(4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3 [[(3S,5S)-5-(sulfamoylaminomethyl)pyrrolidin-3-yl]thio]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid having a diffraction pattern in powder X-ray diffraction having main peaks at diffraction angles (2θ)=13.04, 14.98, 15.88, 16.62, 20.62, 21.06, 22.18, 23.90, 26.08, 28.22 and 28.98 (degrees), or a hydrate thereof.  
     
     
         2 . A medicament containing a crystal according to  claim 1 .  
     
     
         3 . A medicament according to  claim 2 , wherein the medicament is an injection.  
     
     
         4 . A medicament according to  claim 2 , wherein the medicament is a powder filling preparation.  
     
     
         5 . A crystal of (+)-(4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3 [[(3S,5S)-5-(sulfamoylaminomethyl)pyrrolidin-3-yl]thio]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid having a diffraction pattern in powder X-ray diffraction having main peaks at diffraction angles (2θ)=6.78, 6.96, 15.74, 17.92, 21.16, 23.56, and 25.80 (degrees), or a hydrate thereof.  
     
     
         6 . A method for producing a crystal according to  claim 5 , comprising the steps of: 
 (A) dissolving in water (+)-(4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3 [[(3S,5S)-5-(sulfamoylaminomethyl)pyrrolidin-3-yl]thio]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid or a hydrate thereof; and    (B) depositing the crystal from an aqueous solution obtained in step (A).    
     
     
         7 . A method for producing a crystal according to  claim 1 , comprising the steps of: 
 (A) dissolving in water (+)-(4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3 [[(3S,5S)-S-(sulfamoylaminomethyl)pyrrolidin-3-yl]thio]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid or a hydrate thereof; and    (B′) depositing the crystal from an aqueous solution obtained in step (A), wherein a diffraction pattern of the deposited crystal in powder X-ray diffraction has main peaks at diffraction angles (2θ)=6.78, 6.96, 15.74, 17.92, 21.16, 23.56, and 25.80 (degrees); and    (C) drying the crystal obtained in step (B′).

Join the waitlist — get patent alerts

Track US2007060562A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.